NASDAQ:PDEX Pro-Dex (PDEX) Stock Forecast, Price & News $18.99 +0.25 (+1.33%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$18.63▼$19.0050-Day Range$15.50▼$19.0552-Week Range$14.47▼$21.43Volume2,438 shsAverage Volume5,338 shsMarket Capitalization$67.41 millionP/E Ratio14.95Dividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Pro-Dex (NASDAQ:PDEX) StockPro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches. The company was founded on January 26, 1994 and is headquartered in Irvine, CA.Read More Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Email Address PDEX Stock News HeadlinesJune 5, 2023 | finanznachrichten.deStock Day Media: Pro-Dex, Inc. Discusses Record 3rd Quarter Results with The Stock Day PodcastJune 5, 2023 | finance.yahoo.comPro-Dex, Inc. Discusses Record 3rd Quarter Results with The Stock Day PodcastJune 9, 2023 | Edge On The Street (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 2, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Pro-Dex (NASDAQ:PDEX)May 30, 2023 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 23% CAGR over the last five yearsMay 25, 2023 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Coverage Initiated by Analysts at StockNews.comMay 17, 2023 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Receives New Coverage from Analysts at StockNews.comMay 13, 2023 | americanbankingnews.comComparing Pro-Dex (NASDAQ:PDEX) and Teleflex (NYSE:TFX)June 9, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 10, 2023 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Earns Buy Rating from Analysts at StockNews.comMay 4, 2023 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2023 Third Quarter and Nine-Month ResultsApril 23, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Pro-Dex (NASDAQ:PDEX)April 20, 2023 | seekingalpha.comPDEX Pro-Dex, Inc.April 12, 2023 | americanbankingnews.comSensus Healthcare (NASDAQ:SRTS) and Pro-Dex (NASDAQ:PDEX) Financial ContrastMarch 31, 2023 | finance.yahoo.comOne Pro-Dex, Inc. (NASDAQ:PDEX) insider upped their stake by 36% in the previous yearMarch 31, 2023 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Now Covered by StockNews.comFebruary 27, 2023 | finance.yahoo.comPro-Dex's (NASDAQ:PDEX) Returns On Capital Not Reflecting Well On The BusinessFebruary 14, 2023 | finance.yahoo.comPro-Dex, Inc. Discusses 2nd Quarter Results and 2023 Growth Strategy with The Stock Day PodcastFebruary 2, 2023 | msn.comPro-Dex GAAP EPS of $0.24 misses by $0.05, revenue of $11.28M beats by $0.88MFebruary 2, 2023 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2023 Second Quarter and Six-Month ResultsJanuary 30, 2023 | seekingalpha.comPro-Dex Is Growing But Expensive Given Its RiskJanuary 20, 2023 | finance.yahoo.comWhy Pro-Dex, Inc. (NASDAQ:PDEX) Could Be Worth WatchingJanuary 18, 2023 | reuters.comPDEX.A - | Stock Price & Latest News | ReutersDecember 21, 2022 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 19% CAGR over the last five yearsNovember 25, 2022 | msn.comPro-Dex Earnings Perspective: Return On Invested CapitalNovember 23, 2022 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Pro-Dex, Inc. (NASDAQ:PDEX)?November 9, 2022 | finance.yahoo.comPro-Dex First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines PDEX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDEX Company Calendar Last Earnings11/15/2021Today6/08/2023Fiscal Year End6/30/2023Next Earnings (Estimated)8/24/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDEX CUSIPN/A CIK788920 Webwww.pro-dex.com Phone(949) 769-3200Fax949-769-3281Employees117Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.27 Trailing P/E Ratio14.95 Forward P/E RatioN/A P/E GrowthN/ANet Income$3.86 million Net Margins9.72% Pretax Margin11.92% Return on Equity19.00% Return on Assets9.85% Debt Debt-to-Equity Ratio0.36 Current Ratio3.07 Quick Ratio1.58 Sales & Book Value Annual Sales$48.06 million Price / Sales1.40 Cash Flow$1.32 per share Price / Cash Flow14.42 Book Value$6.54 per share Price / Book2.90Miscellaneous Outstanding Shares3,545,000Free Float2,035,000Market Cap$67.32 million OptionableNot Optionable Beta0.99 Key ExecutivesRichard Lee van KirkPresident, Chief Executive Officer, COO & DirectorAlisha K. CharltonChief Financial Officer & SecretaryKey CompetitorsRosecliff Acquisition Corp INASDAQ:RCLFNeuroneticsNASDAQ:STIMMeihua International Medical TechnologiesNASDAQ:MHUADelcath SystemsNASDAQ:DCTHProSomnusNASDAQ:OSAView All CompetitorsInstitutional OwnershipPunch & Associates Investment Management Inc.Bought 7,480 shares on 5/15/2023Ownership: 1.779%Dimensional Fund Advisors LPSold 1,379 shares on 5/12/2023Ownership: 1.616%UBS Group AGBought 4,742 shares on 5/12/2023Ownership: 0.165%LSV Asset ManagementSold 1,200 shares on 5/2/2023Ownership: 0.895%View All Institutional Transactions PDEX Stock - Frequently Asked Questions How have PDEX shares performed in 2023? Pro-Dex's stock was trading at $15.90 at the start of the year. Since then, PDEX stock has increased by 19.4% and is now trading at $18.99. View the best growth stocks for 2023 here. Are investors shorting Pro-Dex? Pro-Dex saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 11,300 shares, an increase of 18.9% from the April 30th total of 9,500 shares. Based on an average trading volume of 4,400 shares, the days-to-cover ratio is currently 2.6 days. Currently, 0.5% of the company's shares are short sold. View Pro-Dex's Short Interest. When is Pro-Dex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023. View our PDEX earnings forecast. How were Pro-Dex's earnings last quarter? Pro-Dex, Inc. (NASDAQ:PDEX) issued its earnings results on Monday, November, 15th. The medical instruments supplier reported $0.28 earnings per share for the quarter, meeting the consensus estimate of $0.28. The medical instruments supplier earned $9.99 million during the quarter. Pro-Dex had a net margin of 9.72% and a trailing twelve-month return on equity of 19.00%. What is Michael J. Berthelot's approval rating as Pro-Dex's CEO? 3 employees have rated Pro-Dex Chief Executive Officer Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among the company's employees. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH). What is Pro-Dex's stock symbol? Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX." Who are Pro-Dex's major shareholders? Pro-Dex's stock is owned by many different institutional and retail investors. Top institutional shareholders include Punch & Associates Investment Management Inc. (1.78%), Dimensional Fund Advisors LP (1.62%), LSV Asset Management (0.89%) and UBS Group AG (0.17%). Insiders that own company stock include Alisha Charlton, Katrina Marie Kramer Philp, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III. View institutional ownership trends. How do I buy shares of Pro-Dex? Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pro-Dex's stock price today? One share of PDEX stock can currently be purchased for approximately $18.99. How much money does Pro-Dex make? Pro-Dex (NASDAQ:PDEX) has a market capitalization of $67.32 million and generates $48.06 million in revenue each year. The medical instruments supplier earns $3.86 million in net income (profit) each year or $1.27 on an earnings per share basis. How many employees does Pro-Dex have? The company employs 117 workers across the globe. How can I contact Pro-Dex? Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for the company is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281. This page (NASDAQ:PDEX) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.